LSM6: A Potential Drug Target Or Biomarker (G11157)

Target Name: LSM6

NCBI ID: G11157

LSM6

LSM6: A Potential Drug Target Or Biomarker

LSM6 (LSM6_HUMAN), also known as human long short-chain non-proteinogenic RNA-6 (LSM6), is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. LSM6 is produced in the human body and is expressed in various tissues and cells, including the brain, heart, and muscle.

The discovery of LSM6 as a potential drug target or biomarker comes from a study by researchers at the University of California, San Diego, who found that LSM6 was expressed in the brains of individuals with Alzheimer's disease and that levels of LSM6 were significantly higher in individuals with the disease compared to those without it. The researchers also found that LSM6 was associated with the presence of beta-amyloid plaques, a hallmark of Alzheimer's disease, in the brain.

Other studies have also shown that LSM6 is involved in the development and progression of various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. For example, a study by researchers at the University of Cambridge found that LSM6 was overexpressed in the brains of individuals with multiple sclerosis, a neurodegenerative disease, and that overexpression of LSM6 was associated with the development of the disease.

In addition to its potential as a drug target or biomarker, LSM6 has also been shown to have potential as a diagnostic tool. A study by researchers at the University of California, San Diego found that LSM6 was expressed in the brains of individuals with amyotrophic lateral sclerosis, a progressive neurodegenerative disease, and that LSM6 was associated with the disease.

The potential uses of LSM6 as a drug target or biomarker are vast and varied. For example, LSM6 has been shown to be involved in the development and progression of various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. As a result, LSM6 has potential as a therapeutic target for these diseases.

In addition to its potential as a therapeutic target, LSM6 has also been shown to have potential as a biomarker for various diseases. For example, LSM6 has been shown to be involved in the development and progression of Alzheimer's disease, and has been associated with the presence of beta-amyloid plaques in the brain. As a result, LSM6 has potential as a diagnostic tool for Alzheimer's disease.

The research into LSM6 is still in its early stages, and much more research is needed to fully understand its potential as a drug target or biomarker. However, the findings of the various studies that have been conducted on LSM6 suggest that it has the potential to be a valuable tool for the diagnosis and treatment of a wide range of diseases.

In conclusion, LSM6 (LSM6_HUMAN) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. The discovery of LSM6 as a potential drug target or biomarker comes from a study by researchers at the University of California, San Diego, who found that LSM6 was expressed in the brains of individuals with Alzheimer's disease and that levels of LSM6 were significantly higher in individuals with the disease compared to those without it. Other studies have also shown that LSM6 is involved in the development and progression of various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. In addition to its potential as a drug target or biomarker, LSM6 has also been shown to have potential as a diagnostic tool. Further research is needed to fully understand its potential and to explore its uses in the diagnosis and treatment of various diseases.

Protein Name: LSM6 Homolog, U6 Small Nuclear RNA And MRNA Degradation Associated

Functions: Plays role in pre-mRNA splicing as component of the U4/U6-U5 tri-snRNP complex that is involved in spliceosome assembly, and as component of the precatalytic spliceosome (spliceosome B complex) (PubMed:28781166). The heptameric LSM2-8 complex binds specifically to the 3'-terminal U-tract of U6 snRNA (PubMed:10523320). Component of LSm protein complexes, which are involved in RNA processing and may function in a chaperone-like manner, facilitating the efficient association of RNA processing factors with their substrates. Component of the cytoplasmic LSM1-LSM7 complex, which is thought to be involved in mRNA degradation by activating the decapping step in the 5'-to-3' mRNA decay pathway (Probable)

The "LSM6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LSM6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets